Clinical trial
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and…
NCT00382668 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00382668 |
|---|---|
| Title | A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug |
| Official title | Single-Dose Pharmacokinetics of Dasatinib in Subjects With Hepatic Impairment Compared to Healthy Adult Subjects |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Liver Diseases |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 40 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Sep 29, 2006 |
| Last update posted | Apr 14, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: